Corbus Pharmaceuticals (CRBP) Competitors $10.47 +0.44 (+4.39%) Closing price 04:00 PM EasternExtended Trading$10.48 +0.01 (+0.14%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRBP vs. CGEM, TNXP, ITOS, GOSS, RGNX, PRTA, TECX, EOLS, PRTC, and REPLShould you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), iTeos Therapeutics (ITOS), Gossamer Bio (GOSS), REGENXBIO (RGNX), Prothena (PRTA), Tectonic Therapeutic (TECX), Evolus (EOLS), PureTech Health (PRTC), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Corbus Pharmaceuticals vs. Its Competitors Cullinan Therapeutics Tonix Pharmaceuticals iTeos Therapeutics Gossamer Bio REGENXBIO Prothena Tectonic Therapeutic Evolus PureTech Health Replimune Group Cullinan Therapeutics (NASDAQ:CGEM) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Do insiders & institutionals believe in CGEM or CRBP? 86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor CGEM or CRBP? In the previous week, Cullinan Therapeutics had 15 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 18 mentions for Cullinan Therapeutics and 3 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.54 beat Cullinan Therapeutics' score of 0.95 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corbus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend CGEM or CRBP? Cullinan Therapeutics presently has a consensus price target of $26.80, indicating a potential upside of 237.96%. Corbus Pharmaceuticals has a consensus price target of $49.00, indicating a potential upside of 368.00%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Cullinan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Which has higher valuation & earnings, CGEM or CRBP? Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan TherapeuticsN/AN/A-$167.38M-$3.23-2.46Corbus PharmaceuticalsN/AN/A-$40.21M-$4.76-2.20 Which has more risk and volatility, CGEM or CRBP? Cullinan Therapeutics has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.2, suggesting that its stock price is 220% more volatile than the S&P 500. Is CGEM or CRBP more profitable? Cullinan Therapeutics' return on equity of -36.56% beat Corbus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -36.56% -34.82% Corbus Pharmaceuticals N/A -43.65%-39.62% SummaryCorbus Pharmaceuticals beats Cullinan Therapeutics on 8 of the 14 factors compared between the two stocks. Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBP vs. The Competition Export to ExcelMetricCorbus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$128.36M$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E Ratio-2.2022.5330.8326.39Price / SalesN/A506.55382.9086.63Price / CashN/A178.3537.7259.11Price / Book1.166.2910.106.62Net Income-$40.21M$32.94M$3.26B$265.42M7 Day Performance13.56%2.27%3.90%3.58%1 Month Performance13.07%1.06%3.73%0.46%1 Year Performance-81.71%5.65%37.68%19.41% Corbus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBPCorbus Pharmaceuticals4.3312 of 5 stars$10.47+4.4%$49.00+368.0%-83.1%$128.36MN/A-2.2040Positive NewsCGEMCullinan Therapeutics1.7328 of 5 stars$7.95+3.8%$28.60+259.7%-58.2%$452.51MN/A-2.4630Analyst RevisionTNXPTonix Pharmaceuticals2.8317 of 5 stars$40.07-22.0%$70.00+74.7%-9.1%$450.13M$10.09M-1.0250High Trading VolumeITOSiTeos Therapeutics2.7118 of 5 stars$10.11flat$15.50+53.3%-43.6%$446.92M$35M-2.1690GOSSGossamer Bio3.6011 of 5 stars$1.99+1.5%$8.50+327.1%+173.9%$445.67M$114.70M-3.21180RGNXREGENXBIO4.344 of 5 stars$8.71-1.2%$28.38+225.8%-24.7%$445.54M$83.33M-2.53370PRTAProthena2.8433 of 5 stars$8.53+3.4%$30.25+254.6%-62.0%$444.10M$135.16M-1.51130Positive NewsTECXTectonic Therapeutic2.1006 of 5 stars$24.71+5.1%$80.33+225.1%+38.3%$439.92MN/A-6.12120Positive NewsEOLSEvolus4.1291 of 5 stars$6.69-0.6%$21.25+217.6%-51.6%$435.33M$266.27M-6.83170Positive NewsGap UpPRTCPureTech Health2.9092 of 5 stars$19.84+10.2%$45.00+126.8%-17.0%$434.61M$4.83M0.00100Positive NewsUpcoming EarningsGap DownREPLReplimune Group3.9014 of 5 stars$5.33-4.1%$7.67+43.8%-44.8%$433.99MN/A-1.65210 Related Companies and Tools Related Companies CGEM Alternatives TNXP Alternatives ITOS Alternatives GOSS Alternatives RGNX Alternatives PRTA Alternatives TECX Alternatives EOLS Alternatives PRTC Alternatives REPL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBP) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access